Thomas Helleday
Thomas Helleday
The DNA damage response (DDR) protein MTH1 is sanitising the oxidized dNTP pool and preventing incorporation of oxidative damage into DNA and has an emerging role in mitosis. It is a stress-induced protein and often found to be overexpresse...
Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers [0.03%]
结合使用PARP抑制剂和免疫疗法治疗BRCA相关癌症
Geoffrey I Shapiro,Suzanne M Barry
Geoffrey I Shapiro
Poly (ADP-ribose) polymerase (PARP) inhibitors have significantly improved treatment outcomes of homologous recombination (HR) repair-deficient cancers. While the activity of these agents is largely linked to multiple mechanisms underlying ...
Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer [0.03%]
用于克服卵巢癌药物耐药性的组合型DNA损伤反应抑制剂
Dimitrios Nasioudis,Erin M George,Haineng Xu et al.
Dimitrios Nasioudis et al.
The DNA damage response (DDR) results in activation of a series of key target kinases that respond to different DNA damage insults. DDR inhibitors such as PARP inhibitors lead to the accumulation of DNA damage in tumor cells and ultimately ...
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents [0.03%]
PARP抑制剂与同源重组修复障碍诱导型靶向制剂的合理联合用药策略
Elizabeth K Lee,Joyce F Liu
Elizabeth K Lee
Cancers with wild-type BRCA, homologous recombination proficiency, or de novo or acquired resistance to PARP inhibition represent a growing population of patients who may benefit from combinatorial PARP inhibitor strategies. We review targe...
Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges [0.03%]
聚(腺苷二磷酸核糖)聚合酶(PARP)抑制剂与化疗药物的联合应用：前景和挑战
Kyaw Zin Thein,Rajat Thawani,Shivaani Kummar
Kyaw Zin Thein
Better understanding of molecular drivers and dysregulated pathways has furthered the concept of precision oncology and rational drug development. The role of DNA damage response (DDR) pathways has been extensively studied in carcinogenesis...
Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors [0.03%]
PARP抑制剂治疗胰腺癌患者的管理策略
Talia Golan,Maria Raitses-Gurevich,Tamar Beller et al.
Talia Golan et al.
A subset of patients with pancreatic adenocarcinomas (PDAC) harbor mutations that are exploitable in the context of DNA-damage response and repair (DDR) inhibitory strategies. Between 8-18% of PDACs harbor specific mutations in the DDR path...
Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer [0.03%]
靶向雄激素剥夺治疗后前列腺癌的PARP抑制剂的研究进展
Kent W Mouw,Atish D Choudhury
Kent W Mouw
Prostate cancer is a genetically heterogenous disease and a subset of prostate tumors harbor alterations in DNA damage and repair (DDR) genes. Prostate tumor DDR gene alterations can arise via germline or somatic events and are enriched in ...
Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer [0.03%]
用于BRCA突变型和非BRCA突变型乳腺癌患者的PARP抑制剂临床应用
Filipa Lynce,Mark Robson
Filipa Lynce
The use of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of patients with germline BRCA mutations (gBRCAm) and breast cancer, both in the early and advanced settings, is a success of genomically-directed treatment. These a...
Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer [0.03%]
卵巢癌中聚(腺苷二磷酸核糖)聚合酶(PARP)抑制剂的临床应用
Melissa M Pham,Monica Avila,Emily Hinchcliff et al.
Melissa M Pham et al.
The treatment of ovarian cancer has remained a clinical challenge despite high rates of initial response to platinum-based chemotherapy. Patients are generally diagnosed at an advanced stage with significant disease burden, which portends t...
Development of Homologous Recombination Functional Assays for Targeting the DDR [0.03%]
同源重组功能测定法靶向DDR的发展研究
Ailsa J Oswald,Charlie Gourley
Ailsa J Oswald
Identification of tumours that have homologous recombination deficiency (HRD) has become of increasing interest following the licensing of PARP inhibitors. Potential methods to assess HRD status include; clinical selection for platinum sens...